fibrosis

Novartis and Pfizer-Backed Mediar Nets $85M for Fibrosis Paradigm Shift
Novartis and Pfizer-Backed Mediar Nets $85M for Fibrosis Paradigm Shift
BioSpace
Mediar Therapeutics
Novartis
Pfizer
fibrosis
Flag link:
Frazier Launches Lassen to Advance Antibodies Against Fibrosis, Cancer
Frazier Launches Lassen to Advance Antibodies Against Fibrosis, Cancer
Xconomy
Lassen Therapeutics
fibrosis
cancer
Flag link:
Galapagos bags option on 4 more Fibrocor programs
Galapagos bags option on 4 more Fibrocor programs
Fierce Pharma
Galapagos
fibrosis
Fibrocor
Flag link:
AbbVie and Scripps Research Enter Research Partnership in Cancer, Immunology, Neurology and Fibrosis
AbbVie and Scripps Research Enter Research Partnership in Cancer, Immunology, Neurology and Fibrosis
BioSpace
AbbVie
Scripps Research Institute
cancer
immunology
fibrosis
Flag link:
Forbius completes enrollment into phase 1a solid tumour trial of AVID200
Forbius completes enrollment into phase 1a solid tumour trial of AVID200
Pharmaceutical Business Review
Forbius
fibrosis
cancer
AVID200
solid tumors
clinical trials
Flag link:
Evotec, Galapagos enter into collaboration in fibrosis field
Evotec, Galapagos enter into collaboration in fibrosis field
Pharmaceutical Business Review
fibrosis
Evotec
Galapagos
Flag link:
Galapagos continues fibrosis pipeline buildout with Evotec deal
Galapagos continues fibrosis pipeline buildout with Evotec deal
Fierce Biotech
Galapagos
Evotec
fibrosis
R&D
Flag link:
AbbVie Commits $100M to Morphic in Fibrosis Drug R&D Alliance
AbbVie Commits $100M to Morphic in Fibrosis Drug R&D Alliance
Xconomy
AbbVie
Morphic Therapeutics
R&D
fibrosis
Flag link:
Bristol-Myers, Nitto Ink NASH, Fibrosis Deal
Bristol-Myers, Nitto Ink NASH, Fibrosis Deal
Investopedia
Bristol-Myers Squibb
Nitto
NASH
fibrosis
Flag link:
Bristol-Myers pens $100M NASH, fibrosis drug deal with Japan’s Nitto
Bristol-Myers pens $100M NASH, fibrosis drug deal with Japan’s Nitto
Fierce Biotech
Bristol-Myers Squibb
M&A
NASH
fibrosis
Japan
Nitto
Flag link:
Biogen Idec scores lung disease drug in $562.5M buyout of Stromedix
Biogen Idec scores lung disease drug in $562.5M buyout of Stromedix
Fierce Biotech
Stromedix
Biogen Idec
M&A
STX-100
fibrosis
Flag link:
Amira Pharmaceuticals to Present Preclinical Data on AM152 , an LPA1 Receptor Antagonist, at the Annual Meeting of the American Thoracic Society
Amira Pharmaceuticals to Present Preclinical Data on AM152 , an LPA1 Receptor Antagonist, at the Annual Meeting of the American Thoracic Society
PR-USA.net
Amira
AM152
fibrosis
Flag link:
Sanofi May Pay Regulus Up to $750 Million in Deal
Sanofi May Pay Regulus Up to $750 Million in Deal
Bloomberg
Sanofi
Regulus
drug development
Isis Pharmaceuticals
Alnylam
fibrosis
Flag link: